On 13 December 2021, the Ethics Committee of the Higher Institute of Health (ISS) gave a favorable opinion on the pilot study called “Action of oxygen ozone therapy (SIOOT protocol) on methicillin-resistant Staphylococcus aureus (MRSA) and in vitro analysis of the effects immunomodulators on human lymphomonocytes “.
Head of the study, which is already underway, is Dr. Alessandra Cenci.
The experimentation has great relevance from a scientific, clinical, health and economic point of view.
MRSA is the acronym for Methicillin resistant Staphylococcus aureus , an acronym that was coined because the first antibiotic to which some strains of Staphylococcus aureus proved resistant was precisely methicillin.
Then the biologists and doctors realized that the resistance of these strains was also directed towards penicillins and cephalosporins, but the term MRSA had now entered the common jargon and was never changed.
Staphylococcus aureus is the cause of a multitude of infections such as folliculitis, furunculosis, sty, impetigo, toxic shock syndrome, burned skin syndrome, infectious cellulitis, bacterial pneumonia, osteomyelitis , septic arthritis, septic bursitis, mastitis, bacterial endocarditis …
Furthermore, in the presence of a staphylococcal infection, it is possible that infectious bacteria may develop in the bloodstream: a phenomenon known as “bacteremia” which can give rise to metastatic foci of infection.
Persistent bacteremia can escalate to sepsis and septic shock. In the latter cases, the mortality of the affected patients can reach 70%.
Together with the severe damage in terms of loss of life, MRSA also generates enormous losses from an economic point of view.
Considering that almost all patients develop antibiotic resistance after surgery and during their hospital stay, the minimum amount of compensation for damage suffered as a result of MRSA is 200,000 euros.
To get an idea of how terrible MRSA is, a study carried out in the United States in 2008 by the Association for Professionals in Infection Control and Epidemiology calculated that there were 1.2 million hospitalized patients in one year who had contracted a disease. Methicillin-resistant Staphylococcus aureus (MRSA) infection. And the deaths had been about 119,000.
According to a WHO Report released on November 27, 2021, antimicrobial resistance (AMR) is one of the top 10 global public health threats humanity faces, and requires urgent multisectoral action in order to achieve the goals. sustainable development (SDG):https://ahpsr.who.int/publications/i/item/global-action-plan-on-antimicrobial-resistance
The first to propose to use oxygen ozone therapy to counteract and overcome antibiotic resistance was prof. Marianno Franzini, current international president of SIOOT (Scientific Society of Oxygen Ozone Therapy), who, during a hearing at the XII Social Affairs Commission of the Chamber of Deputies held on 4 July 2019, explained that ozone, with the its high oxidative potential, is particularly useful in the prevention and treatment of infections in all areas (hospital, home, animal breeding, etc.), as well as for the treatment of water (legionellosis) and air.
In this regard, prof. Franzini explained to the members of the Commission the methods of treatment successfully practiced on numerous patients suffering from antibiotic resistance: patients who had post-operative wounds that did not heal, resistant pneumonia, infections of different types after prostheses that lasted for months and that could not find a solution .
Following the hearing in Parliament and the clinical work carried out in the meantime, in September 2020 a collaboration agreement was signed between SIOOT and the Catholic University of the Sacred Heart to carry out a joint research project called “Multicenter clinical study on evaluation of the efficacy of Oxygen-Ozone therapy in combination with antibiotic therapy “.
Scientific director of the project is prof. Walter Ricciardi, former Commissioner and then President of the Istituto Superiore di Sanità (ISS).
The agreement now signed with the Istituto Superiore di Sanità completes and validates an experimentation path that could give a decisive answer in the global fight against MRSA. And it would be an unprecedented success for Italian medical research and for the health of the entire planet.
Antonio Gaspari Director Orbispherawww.orbisphera.org